Kimberly Kelly is an Associate Professor of Biomedical Engineering and a preceptor on the Pharmacology Training Grant at the University of Virginia School of Medicine. Dr. Kelly recently made the headlines of UVA Today for securing funding for the development of a new drug called ZB131, an antibody designed to target plectin found on the surface of multiple types of cancer cells. Visit UVA Today for the full story.
Kudos to Kimberly Kelly: Promising Cancer Drug Attracts $25 Million in Funding
February 6, 2020 by email@example.com